Drug Trial Radar · NCT05403710
Targeting Nociceptors in Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jun 7, 2022
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- University of Massachusetts, WorcesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hidradenitis Suppurativa Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); AbbVie
- First posted
- Jun 3, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Conditions
- Hidradenitis Suppurativa
- Hyperhidrosis
Interventions
Botulinum toxinDrug
Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment.Time frame: 1-2 months after first treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.